Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQW051 for Cognitive Function in Schizophrenia
NCT01163227Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2010
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AQW051 in schizophrenia (4 arms), sponsored by Novartis. Primary endpoint: Effects of single oral doses of AQW051 versus placebo on cognitive function as measured by selected CogState tests at 121 days. Started May 2010; status: completed.
02
Drugs
AQW051
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01163227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01163227.